Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05038735
Title	Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5)
Acronym	EPIK-B5
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	Her2-receptor negative breast cancer
Therapies	Alpelisib + Fulvestrant Fulvestrant
Age Groups:	adult \| senior
Covered Countries	SVK \| ROU \| POL \| ITA \| IRL \| HUN \| GRC \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BGR \| BEL